Boston Scientific Corp.

On the heels of its recently announced acquisition of IoGyn Inc., Natick-based pharmaceutical company Boston Scientific Corp. (BSX) announced it will acquire the Interventional Division of Bayer AG for $415 million in cash.

Boston Scientific said it received a subpoena last week from federal regulators, seeking documents about some of its heart devices.

Natick-based pharmaceutical company Boston Scientific Corp. (BSX) announced it will acquire IoGyn Inc, a clinical-stage company that has received FDA approval on a system designed to treat uterine fibroids and polyps.

In a move it believes will improve its position in the Japanese drug-eluting stent market, Natick-based Boston Scientific Corp. (BSX) announced Thursday the launch of Promus Premier Stent System in the Asian country.

Boston Scientific, lifted by growth in cardiac-treatment devices, reported a 4-percent jump in operational revenue for the first quarter along with net profits of $133 million, rebounding from a $454 million loss in the first quarter of 2013.

Natick-based Boston Scientific Corp. (BSX) has received approval for its newest defibrillators and heart failure devices, including the trademarked Dynagen Mini, Inogen Mini ICDs, and the Dynagen XF and Inogen X4 CRT-Ds.

Natick-based Boston Scientific has expanded the rollout of its implantable defibrillator into parts of Asia.

The Marlborough Economic Development Corp. (MEDC) touted figures from two firms specializing in commercial real estate that highlight the city's position as a stronghold for the commercial office market in the Interstate 495 area.

Rising sales and cost cuts boosted Boston Scientific's fourth-quarter profit significantly over 2012, the company reported.

A ban on U.S. sales of the Guidezilla catheter made by Boston Scientific (BSX) went into effect yesterday after a federal appeals court ruled against BSX's petition for an interim stay.